Dow Jones

38,686.32

1.51%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

IMRX

Immuneering (IMRX)

Immuneering Corporation

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMRX

1 2 3 4 5 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
29/05/2024	15:05	GlobeNewswire Inc.	Immuneering to Present at the Jefferies Global Healthcare Conference	NASDAQ:IMRX	Immuneering Corporation
23/05/2024	15:20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMRX	Immuneering Corporation
23/05/2024	15:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMRX	Immuneering Corporation
07/05/2024	15:05	GlobeNewswire Inc.	Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates	NASDAQ:IMRX	Immuneering Corporation
06/05/2024	15:30	GlobeNewswire Inc.	Immuneering Recognizes Melanoma Awareness Month	NASDAQ:IMRX	Immuneering Corporation
09/04/2024	11:00	GlobeNewswire Inc.	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models	NASDAQ:IMRX	Immuneering Corporation
03/04/2024	15:05	GlobeNewswire Inc.	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:IMRX	Immuneering Corporation
27/03/2024	07:00	GlobeNewswire Inc.	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	NASDAQ:IMRX	Immuneering Corporation
14/03/2024	06:00	GlobeNewswire Inc.	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	NASDAQ:IMRX	Immuneering Corporation
12/03/2024	07:00	GlobeNewswire Inc.	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	NASDAQ:IMRX	Immuneering Corporation
11/03/2024	07:00	GlobeNewswire Inc.	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors	NASDAQ:IMRX	Immuneering Corporation
05/03/2024	16:00	GlobeNewswire Inc.	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024	NASDAQ:IMRX	Immuneering Corporation
04/03/2024	07:00	GlobeNewswire Inc.	Immuneering to Participate in the Cowen 44th Annual Health Care Conference	NASDAQ:IMRX	Immuneering Corporation
01/03/2024	07:05	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:IMRX	Immuneering Corporation
01/03/2024	07:00	GlobeNewswire Inc.	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	NASDAQ:IMRX	Immuneering Corporation
20/02/2024	07:00	GlobeNewswire Inc.	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer	NASDAQ:IMRX	Immuneering Corporation
16/01/2024	15:37	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:IMRX	Immuneering Corporation
12/12/2023	07:00	GlobeNewswire Inc.	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	NASDAQ:IMRX	Immuneering Corporation
20/11/2023	15:05	GlobeNewswire Inc.	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference	NASDAQ:IMRX	Immuneering Corporation
09/11/2023	15:12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMRX	Immuneering Corporation
09/11/2023	15:05	GlobeNewswire Inc.	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates	NASDAQ:IMRX	Immuneering Corporation
12/10/2023	15:05	GlobeNewswire Inc.	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference	NASDAQ:IMRX	Immuneering Corporation
04/10/2023	15:05	GlobeNewswire Inc.	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	NASDAQ:IMRX	Immuneering Corporation
06/09/2023	07:00	GlobeNewswire Inc.	Immuneering to Present at the Morgan Stanley Healthcare Conference	NASDAQ:IMRX	Immuneering Corporation
03/08/2023	15:05	GlobeNewswire Inc.	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates	NASDAQ:IMRX	Immuneering Corporation
15/06/2023	15:40	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:IMRX	Immuneering Corporation
15/06/2023	15:17	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:IMRX	Immuneering Corporation
05/06/2023	07:00	GlobeNewswire Inc.	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors	NASDAQ:IMRX	Immuneering Corporation
30/05/2023	07:00	GlobeNewswire Inc.	Immuneering to Present at the Jefferies Healthcare Conference	NASDAQ:IMRX	Immuneering Corporation
05/05/2023	10:54	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:IMRX	Immuneering Corporation